Publicaciones en las que colabora con Rafael Maldonado López (15)

2022

  1. Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome

    eLife, Vol. 11

2021

  1. Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice

    Psychopharmacology, Vol. 238, Núm. 7, pp. 1923-1936

  2. Role of the endocannabinoid system in a mouse model of Fragile X undergoing neuropathic pain

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 6, pp. 1316-1328

2020

  1. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

    Clinical Nutrition, Vol. 39, Núm. 2, pp. 378-387

  2. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions

    Aging, Vol. 12, Núm. 20, pp. 19923-19937

2019

  1. Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome

    Neurobiology of Disease, Vol. 125, pp. 92-106

  2. Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression

    Cerebral Cortex, Vol. 29, Núm. 7, pp. 2978-2997

  3. Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2

    Brain, Behavior, and Immunity, Vol. 81, pp. 399-409

2017

  1. CB1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal

    Biological Psychiatry, Vol. 81, Núm. 7, pp. 625-634

2015

  1. Cognitive impairment induced by delta9- tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors

    PLoS Biology, Vol. 13, Núm. 7

  2. Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain

    Pain, Vol. 156, Núm. 10, pp. 2001-2012

2013

  1. Targeting the endocannabinoid system in the treatment of fragile X syndrome

    Nature Medicine, Vol. 19, Núm. 5, pp. 603-607

2011

  1. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses

    Biological Psychiatry, Vol. 70, Núm. 5, pp. 479-486

2007

  1. Behavioural and neurochemical effects of combined MDMA and THC administration in mice

    Psychopharmacology, Vol. 195, Núm. 2, pp. 255-264

2004

  1. The rewarding properties of MDMA are presented in mice lacking μ-opioid receptors

    European Journal of Neuroscience, Vol. 20, Núm. 3, pp. 853-858